沃博聯公司 (WBA) 2003 Q3 法說會逐字稿

Good morning, my name is Theresa, and I will be your conference facilitator.

At this time I would like to welcome everyone to the Option Care third quarter earnings conference call.

All lines are placed on mute to prevent any background noise.

After the speakers' remarks there will be a question and answer period.

If you would like to ask a question during this time, simply press star, then the number 1 on your telephone keypad.

If you would like to withdraw your question, press star-2 on your telephone keypad.

Thank you.

Mr.Rajat Rai, you may begin your conference.

Good morning, thank you for joining the third quarter earnings conference call.

Also participating on the call with me are Rick Smith, our president and Chief Operating Officer, Paul Mastrapa, our Chief Financial Officer and Joe Bonaccorsi, our Legal counsel.

By now you have should have received a copy of the press release issued by the company this morning.

If you have not received it call the 847-229-7731, and it will be faxed to you promptly.

Please be advised in keeping with the SEC Reg FD guidelines this call may be accessed by one cast at www.optioncare.com.

Any remarks that Option Care may make about future expectations, plans and prospects for Option Care constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements.

As a result, the various important factors including those included in Option Care's operating results on form 10-K, for the year ended (inaudible audio) which is on file with the SEC.

Option Care anticipates that subsequent events and developments may cause its stipulates to change or it may elect to update these forward-looking statements at some point in the future.

Option Care specifically disclaims any obligations to do so.

Now I would like to give the highlights for the quarter.

Rick and Paul will give the updates on the operations and key financial highlights later in the call.

As discussed previously, and noted in the press release issued this morning we reported $82 million in revenues for the third quarter.

This represented a 5% growth on same store basis from the same time frame in 2002.

The earnings for the quarter were a loss of 14 cents a share, which included restructuring costs, certain one-time costs and reserves for Texas operations of 24 cents a share.

Prior to the impact of these charges, our earnings for the quarter were 10 cents a share.

We remained focused on cash flow and continued to make progress.

We were cash flow positive from operations by $10 million in the second quarter, and further improvement from the second quarter.

Sales were essentially flat in the third quarter from the second quarter of this year after we factored out the seasonal sales of Synagis.

A number of issues resulted in lower than expected sales volume.

Within the home and fusion sluggish (inaudible) by hospitals nationwide and shorter duration of therapies resulted in flat sales.

Sales for managed care driven specialty pharmacy remain flat and saw a shift toward lower margin products.

These factors coupled with hard costs related to liability, health insurance, resulted in lower than expected earnings.

In the third quarter we took immediate steps to bring our costs in line with the current level of sales and streamline our operations and have effectively restructured our organization.

These are the following steps we took in the third quarter.

First, we eliminated the middle management of field operations to gain more visibility for our operations and effectively communicate the company's strategy and tactical plans to the general managers.

Combined with specialty pharmacy and infusion businesses in Ann Arbor and Fort Lauderdale to eliminate redundant overhead cost.

We reduced operating overhead in every corporate office.

We exited unprofitable whole health nursing business in Fort Lauderdale location.

Finally, we hired a new vice president of sales to manage both our home and fusion specialty pharmacy businesses and have revamped the sales organization that will drive the top line growth.

As I mentioned in our previous call, our focus in the fourth quarter and moving forward revolves around growth and control costs.

We have revamped our sales organization that can effectively cross sale both home and specialty pharmacy to managed care, manufacturers and physicians.

In addition to augmenting our sales efforts, we have hired Kirby Ryan who has over 15 years of experience in pharmaceutical and specialty pharmacy industries.

Kirby will be responsible for all sales efforts to execute our manufactured-driven specialty pharmacy business includes developing relationships and launching new products.

As we see today we have stability in our sales from the third quarter.

In addition we are focused in launching Synagis and Xolair (ph) and excited about the opportunities for growth.

The (inaudible) and momentum and our sales effort in all our markets in both lines of business.

We expect revenues in the fourth quarter to be in the range of $90 million to $91 million, and earnings in the range of 16 to 17 cents a share.

While we focus on top line growth we remain focused on controlling costs, improving profitability through high margin therapies and finally cash flow.

We are also looking forward acquisitions and remain optimistic of the opportunities, particularly in the home and home infusion segment.

We are currently working on our business plan and will issue guidance for 2004 by the end of this year.

I will now turn the call over to Rick Smith our president and Chief Operating Officer.

Thanks, Rajat.

Good morning, everyone.

We stated several weeks ago that we had substantially completed our reorganization of sales and the operating structure of the company.

We have spent the time since that announcement rapidly bringing urgent focus to in renewed sales growth and operational efficiency.

We announced that Don Carlberg had joined us as Vice President of Sales were directed through Don.

We have added additional managed care sales professionals and have increased the focus of our physician sales force.

We also increased our sales leadership with the addition of Kirby Ryan who will increase sales to manufacturers and strengthening our specialty sales efforts.

We have had a significant amount of focus on generating revenue momentum into Q4 to position us well going into next year.

Over the last three weeks we have identified many core and specialty revenue opportunities that exist in each of our markets.

We have also met with a number of payers to review opportunities for increased referral activity and pull-through opportunity.

We have also renewed the effort of the focus of the entire organization on increased sales of our core infusion services and higher margin specialty products.

Several new clinical programs have been introduced to the field during the third quarter and we looked to see a positive impact on core revenues in Q4.

We have also been creating awareness of our new clinical resources network for clinical trials and post-marketing study.

The interest from both manufacturers and biotech companies have been very encouraging.

On the bright operating side of the business, we have continued to update field management staff and focus on operating cost controls to ensure our operating efficiency going forward.

We have continued to identify opportunities to improve our operating efficiency, we have taken significant steps to monitor that our cost reduction programs that we have put in place are working as we had projected.

We have enhanced our management reporting system and are improving our complex therapy staffing model at the local levels to ensure the delivery of a low cost service.

We are also looking at ways to enhance our operating model to work better with our customers in all areas of customer service.

And the reimbursement area, the overall focus on a good front end process in each of our locations has been successful.

We continue to see very good cash flow performance from our location.

We are very focused on reducing our day sales outstanding to the lowest level possible at each of our locations.

In the Texas market, the cash flow from current billings have been very positive.

We have work to do in cleaning up old account as we attempt to collect every single dollar from payers on the receivables.

However the progress so far has been very good.

We will continue to strive to improve our cash flow generation and working Capital Management from each of our locations.

We continue to train our employees in order to create the most technical reimbursement talent in the industry.

We are also looking at our service mod toll enhance our future performance.

Overall, we are very confident that the changes we have made and will continue to make while very positive impact on Q4 results and position us very well going into 2004.

With that I'll turn it over to Paul Mastrapa.

Thanks, Rick, and good morning.

For the third quarter, our revenue was $82.4 million, a 2% increase from the $80.9 million reported in the third quarter of 2002.

Prior to the revenues from the two operating locations sold earlier this year same store growth for infusion and specialty pharmacy business was 5% for the quarter.

The net loss for the quarter was 3 million, as compared to net income of $3.9 million for the third quarter of last year.

Loss per share was 14 cents, as compared earnings per share of 19 cents for the third quarter 2002.

As previously announced, the company recorded a pretax charge of $8.7 million, or 24 cents per diluted share during the third quarter.

Of the $8.7 million charge $6.8 million pertains to additional bad debt reserves for Texas operations $1 million in restructuring costs and $900,000 in an asset write-down and other miscellaneous expenses.

For the nine months ended September 30, 2003, revenues increased 13% to $260 million from $229 million for the prior year period.

Net income for the first nine months including the 24-cent charge was $4.7 million, or 22 cents per diluted share as compared to $11.1 million or 53 cents per diluted share in 2002.

Q3 charge, because $7 million in aged receivables related to Texas operations.

As we completed our analysis on the collectability of these receivables during the third quarter, which included a claim by claim review, we confirm these receivables have a high write-off risk and increased our reserves accordingly by $6.8 million.

The issues with the receivables include for example lack of proper pay authorization, family filing limitations, lack of insurance coverage or age to patient account balances.

Positive note, as Rick mention, the operating team in Texas is in place, we continue to see improving cash flow on short-term revenues, and are commit to the marketplaces we serve.

Restructuring costs incurred during third quarter amounted to approximately $1 million.

These are primarily severance expenses and other personnel costs.

Finally the unusual cost of $900,000 which is surprised of $400,000 for asset write-down on development cost for purchasing system currently under development.

Interest expense of $150,000 related to final payout on an acquisition completed in 2002.

And the remainder in other unusual costs such as expenses associated with launch of Xolair.

For total charges in the third quarter approximately $8.7 million,$7.4 million are non-cash related costs.

Overall gross profit for the third quarter declined to 30%, as compared to 31.4% for the prior year quarter.

Due to a combination of the revenue mix between infusion and specialty pharmacy services, as well as therapy mixed within our infusion business.

In terms of revenue mix, the higher margin in infusion therapy comprised 41.2% in the third quarter this year as compared to 43.1% for the prior third quarter.

Infusion and related healthcare related services gross profit was 40.2% as compared to 42.1% the prior year third quarter.

Reduce infusion gross profit is due to a shift towards higher antibiotics therapies.

Specialty pharmacy services gross profit was 19.2% for the third quarter this year as compared to 19.1% for the prior year period.

SG&A expense as a percentage of revenue 23% for third quarter of 2003, prior to the $8.7 million charge as compared to 21% last year.

The increase in operating expenses as a percentage of revenue was a result of the following factors.

Incremental costs related to infusion system or information system implementation, corporate and field based reimbursement expense, higher branch operating cost, launch cost for clinical trial division and other operating costs in particular liability, health insurance and creation of internal audit function.

Now to summarize cash flow.

Option Care had another quarter of outstanding cash flow.

Generated $10.4 million of positive operating cash flow during third quarter.

Year to date our cash flow from operations totals $23 million.

The cash used in investing activities for the quarter was $3.5 million broken down as follows. $2.5 million for prior period acquisition obligations and $1 million for equipment purchases infrastructure improvement and revenue producing medical equipment.

The remaining contingent acquisition liability apartments to under $1 million.

Our strong cash flow is a reflection of continued improvement in accounts receivable, day sales outstanding were 66 days at the end of the quarter a decrease of 9 days from the previous quarter primarily as a result of the additional reserves for the Texas operations.

However, day sales outstanding for our non-Texas locations were 64 days at the end of the quarter reduction of 3 days from the previous quarter.

Lastly wind ended third quarter virtually debt free cash offsetting balance sheet.

For fourth quarter we expect revenues $90 million to $91 million, increase from the third quarter attributable to the start of the Synagis season.

We expect earnings per share to range between 16 to 17 cents.

We'll issue 2004 guidance late this year as we complete our planning process.

Now I would like to ask the operator to open the call to questions.

Thank you, sir.

As a reminder, at this time if you would like to ask a question, please press star, then the number 1 on your telephone keypad.

We will pause for just a moment to compile the Q & A roster.

Your first question comes from Grant Jackson of First Analysis.

Good morning, gentlemen.

Good morning.

A couple questions.

Firstly, the expense for Xolair, to start of that Xolair program, I'm wondering why you included that in the charge rather than just as part of continuing operations.

And the second one was, what kick starts revenue growth?

You know, what would you attribute to company-specific milestones and what are industry factors, and within those industry factors what exactly are you looking for, and are we talking about potentially a Medicare catalyst on the managed care side, and for increase in discharges from the infusion site could you elaborate on what you're looking for?

Grant, this is Paul, I'm starting with the Xolair costs.

You know, those are -- those expenses are included in our continuing operations, as are all the charges that we've talked about.

Our objective in specifically highlighting the Xolair cost was to note it as an unusual expense in the quarter as we're launching that program.

The total effect of our Xolair launch is however is fairly immaterial.

Okay.

This is Rick.

On the revenue opportunity, on the core infusion through the managed care relationships, we have -- we have identified opportunities with our existing relationships where we have not fully explored the opportunities nor received our fair share of pull-through.

We have identified a number of our markets where we have good opportunity given our locations, our positions, and our staffing to generate some additional pull-through in the fourth quarter.

We also believe through a forecast and planning for next year, that there are significant market opportunities across our entire network to generate growth opportunities that we see given the renewed focus on getting the managed care pull-through and also the increased efforts on our physician sales force.

And would you I guess just reiterating what you said to a certain extent, does that mean that you expect it to be more of a maturing of the new sales team and the restructuring process that will kick start sales rather than say, any sort of industry factors or other things?

Yeah, I think clearly we anticipate a level of growth in the industry, consistent with the industry would expect, but we believe through the heightened focus under Don's leadership, and bringing all of our sales force together, speaking as one company, but selling the flexibility of our distribution system and our clinical capability, that there's been some untapped opportunity that have existed in our marketplace, and we're running very hard to take advantage of our presence in our relationships to drive revenue growth.

And does that -- you know, when you're looking to these opportunities, from a strategic standpoint, does that mean you're leaning towards over the longer term more towards the specialty side of the business or on the infusion and other home health side?

I think what we're leaning toward is a balanced opportunity of selling our clinical capability along all of our lines of business.

I think that there's been a level of focus in the past just given how fast the company has grown and the opportunities presented to it, given the reorganization, the restructuring, plus bringing in some fresh eyes to opportunities, we have an opportunity to look at the entire company and see the great potential that we have in growing organically in all of our marketplaces through the relationships we have and the new ones that we'll develop the rest of this year and into next year.

Thanks.

Your next question is from David McDonald of Leerink (ph) Swann.

Good morning, guys.

Just a quick follow-up on that.

In terms of the sales force and you're talking about additional pull-through, et cetera, can you run through some of the metrics that the sales force is going to be judged by and what their comp is tied to?

And then any specific programs that have been launched out in the field that are new or is it just a case of more focus on existing clients?

And then I have a couple follow-ups.

Okay.

First of all, on the commission structure, we amended and re-launched our commission structure to the field sales people October 1st, to make sure that there is a significant amount of Q4 focus on our higher margin based business and sperm at this therapies.

We also had just brought in the managed care sales force in the last week and a half and have given them revenue-specific goals to achieve with some good commission opportunities for success.

We've also put down additional revenue targets for each of our branch locations to essentially run to achieve given Q3 levels and Q4 focus, as well as 2004 focus.

Commission plan is essentially uncapped.

We want to drive performance and drive profitable therapies.

We also are identifying key clinical personnel within our organization that are relied on in terms of customer care sales generation, sales consulting, and have also included them in the bonus opportunities to drive a significant focus in the areas we want to be successfully growing our patient census.

As it relates to new clinical programs that we have rolled out, we mentioned that we did launch our new national hemophilia program in selected markets, where we don't have a significant amount of business in this area, we do have some level of patients and we have some good product managers over this business that we think there's some low hanging fruit that provides us some good opportunities in selected marketplaces.

We also have been re-launching our nutrition program to both the owned lobbying and the franchised locations, and in addition to some refocus on some antibiotic opportunities in a local marketplace with a strategic alignment with a pump manufacturer.

So we're trying to differentiate ourselves and to re-establish our presence in the core area.

And on the specialty side, we continue to focus on our opportunities both in the option med and improving our mix in our pull-through and then also out of our Ann Arbor specialty division, continuing to increase the growth hormone and HEP-C and clearly also the Xolair opportunities that provide ourselves in Q4 and going into 2004.

On the Synagis side, we continue to drive a good focus in that area, we have some good expectations in terms of the growth year over year, going into this season, having been selected as a national home health provider by MEDIMUNE, to deliver this special therapy.

We feel very good about the renewed focus, the opportunities for enhancing our relationships, and some renewed energy in the sales force every day that they take the field.

And Rick, I realize it's only about a month since our last update, but have you guys, you know, with refocusing on some of the nutritional products, perhaps, have you guys seen or expect to see any change in the duration of patients in would you expect to see the duration of patients start to extend back out as we get into 2004?

David, this is Rajat, the nutrition patients are typically longer duration patients.

Exactly.

So that's really our hope and that's the goal we're driving towards achieving.

Okay.

Paul, can you just quickly give me a DSO goal that you guys are looking for in 2004, and if I could just get a quick update on the IT systems, how many locations has this been rolled out, to you know, where are we in that process?

Thanks.

You know, as I mentioned, our total DSOs, about 66 days.

We think there's an opportunity to continue to improve our DSOs through further tightening down of our reimbursement processes in the field through additional training.

And in particular through the greater utilization of electronic claims submission.

Our internal goal overall David for 2004 is to continue to see -- continue to drive down a reduction in DSOs, we would like to see ourselves in the mid 50s.

Okay.

But again depending on how quickly we can move on some of these initiatives it could either better or right around there, but that's our goal.

And Paul, I would assume that's the same store goal because I know acquisitions are going to impact your DSOs and their collections are typically high center.

That's correct.

Okay.

On the system side, David --

Yep.

You know we continued to roll out during the third quarter and man to roll out given our fourth quarter initiatives and restructuring, we've slowed down the rest of the year, the additional implementation, we're continuing to do work behind the scenes in terms of strengthening the operating system and bringing the system here to corporate internally.

Right now it's been outsourced to an outsource vendor, hosting vendor so that lease comes up early in next year, so we're doing work to strengthen and bring control of that into our location.

I held off on the additional installations planned for Q4 because of the initiatives that we rolled out and wanted them to stay focused on generating revenue growth and driving the operating results that we desire.

And so, you know, we are still mapping out our plan to be substantially rolled out into 2004.

We'll probably take this opportunity and this window to increase the functionality in a couple of areas of the system.

But you know, right now our focus is on delivering our operating results and regaining the momentum going into 2004.

Okay, thanks, guys.

Your next question comes from Anne Barlow of Southwest Securities.

Good morning.

A couple questions.

Looking at your revenue targets for the fourth quarter, just wondered where you expect margins to go as far as D&A, your gross profits, et cetera.

There's obviously in our model, needs to be significant improvement with the revenue targets you've got out there.

So could you kind of walk us through your expectations in.

Sure.

Based on your expectations, Anne for the fourth quarter, I would expect our gross, first at the gross level, our overall gross margins to be somewhere between 28% to 29%, with a reduction primarily being driven by the increase in our Synagis.

Right.

Revenues.

In terms of our operating expenses, I'd expect to see those drop to about 19% of revenues, primarily partially as a result of our growth in revenues, but also taking into account the cost reductions we've implemented in the third quarter.

In terms of bad debt, I -- I expect bad debts to range around 2% to a little under 2%.

The historically we've run at around two to slightly over, part of the reason over the last year or so, that's been our run rate.

Part of it was reserving at a higher rate in Texas, as we were dealing with our receivable issue, now that we've booked additional reserve, Texas is -- and we've got confidence in our short-term receivables, Texas is coming down to more of our same store run.

Okay.

And D&A is going to remain pretty much at this level?

Yes, D&A is fairly consistent, you know, our overly CAPEX for year would expect to be about $5.6 million.

We're about a million in CAPEX for Q3 and expect to be no more than a million for Q4.

Next year, we'd expect to remain at around the $4 million to $5 million range in terms of cap ex but we'll give more color on that when we issue our guidance for next year.

All right, thanks.

Your next question comes from Mitra Ramgopal (ph)from Sidoti.

Good morning, guys, just a couple questions.

With regard to the guidance for the third fourth quarter fourth quarter how much of the increase is a result of the cost saving restructuring you have just completed, and if you can give us some color also with regards to your expectations, Synagis revenue relative to what we saw in the first quarter or 4Q of last year.

In terms of the Synagis revenues, you know, our goal, I think as Rick mentioned overall, is to grow that approximately 20% to 25%, which has been I think consistent with what MEDIMUNE is expecting taken into account our overall growth.

That's one of the things. -- one of the things is some payers are pushing back the start date of the season to the beginning of November, which doesn't affect the overall revenues in the season because it ends up extending it on the back end but may affect the overall growth rate that we see in the fourth quarter.

We're just starting to get some visibility on that so it's really too early to tell what that's going to be.

In terms of the Q4 guidance, as we said in the pre-release we expect 5 cents a savings per quarter.

The net savings per share on cost reduction that is we've implemented, and those are factored into our estimates for the fourth quarter.

We're monitoring that on a daily and weekly -- weekly basis depending on upon the expense and have a high degree of confidence in the impact they'll have.

Mitra Ramgopal Thanks.

Your next question comes from John Ransom of Raymond James.

Hey, guys, this is Tony Ratigan (ph) for John ransom.

Quick question from for you regarding your proposed thoughts on the AWP reforms as it relates to Medicare drug reimbursement.

And I guess the latest proposal out there suggests going from AWP minus 5 to AWP minus 15 and I guess in '05 going to an ASP-plus 4% reimbursement methodology.

And specifically, I was wondering first what your thoughts were on how that ASP might play out.

And second what impact or implication that's might have longer term for your oncology business.

I think it would be -- would push more doctors out of the business and maybe increase your share in that market and add some new contracts.

Tony, this is Raj.

As far as the regulation concerned with the AWP reform, you know, first of all the Medicare exposure that we have in minimal.

Number two, it will be a pretty complex process to determine or develop the ASP, so it would be very hard for me to comment on what that would mean to our business.

In terms of reimbursement and pricing.

Gotcha.

And as far as the long-term impact to our managed care-driven, you know, specialty business, I see tremendous opportunities obviously as this change goes through would have a greater opportunity and visibility with not only with Medicare but also with other advantage care opportunities in holding back on making decisions on removing the reimbursement away from physician's office to companies like ourselves.

Gotcha, thank you.

And quick follow-up.

What is your latest payer mix?

Do you have that available?

Yeah, we have about 82% managed care and the remainder is a combination of Medicaid and Medicare.

Great, thanks a lovment I appreciate it.

As a reminder to the participants, if do you have a question, please press star, then the number 1 on your telephone keypad.

Your next question is a follow-up question from Grant Jackson of first analysis.

Raj, could you comment on the competitive environment in specialty as well as industry growth?

I guess one thing, are you seeing managed care organizations pressuring utilization at all, and is that in any cramping industry growth?

And then on the competitive environment front, the PDM’s have posted pretty big specialty increases and trying to figure out where they're getting it from.

Whether it's in some of the lower margin, higher margin therapies and what that means for your business?

Grant, first of all, the whole specialty pharmacy segment is pretty substantial.

So, as it gets more competitive, obviously we'll have to tweak a model a little bit to be in line with where competition is going.

As far as managed care is concerned, obviously they're always looking to lower position, lower cost.

And we have a good strategy working with the managed care organization, and we have a strategy in place to work with those managed care organizations.

And would be exposure of new drugs, I think the industry is poised to grow.

Managed care is going to look for a partner who can help, number one, deliver those pharmaceuticals, along with working with the manufacturers to their members at a reasonably priced product as well as service.

So, we see good opportunities in that industry.

Do you have an estimate of what you think the industry will grow over the next year?

It seems like a lot of people are ratcheting down expectations.

Again, it's going to be based with how new products come out in the marketplace, Grant, and -- but we see, you know, 10% to 15% growth rate as an attainable number for that growth.

Okay.

For your growth or you're saying just for the industry as a whole?

Both.

Okay.

Your next question is from Jeff Allen of Silvercrest Asset Management.

Hi, good morning.

Just wondered if you could comment on how sales are going so far in the fourth quarter, and secondly, just wanted to ask about how you get comfortable removing some of the middle management in the field, you know, I guess the IT systems would help with that, but it seems like you're slowing down the I am policemen's there.

So, you know, how do you sort of get comfortable with having fewer people in the middle management?

First of all, on the early indications on Q4 sales, we're seeing early results of our efforts and our focus.

You know, we are continuing to focus on the two months that we have left as well, so continue to stair step.

Fourth quarter is typically a good, strong seasonal quarter on the core infusion side and we're also seeing some opportunities to perhaps get some pull-through on the specialty businesses as well.

As it relates to the information systems or the elimination of management to field -- at the field level, we have enhanced our management reporting systems here corporately, to where we have access from the local level of a lot of our operating statistics, our revenue generation, the amount of revenue we bill each day, and so from a management reporting system, we have good visibility.

We have a closeness with our field operations and our general managers through the operating structure we put in place, to ensure that we hit our objectives.

So we feel that we really don't lose anything by the delay in the roll-out of emphasis, but we increase our focus and the other programs and the other work that we've been doing in order to come together closer as an organization with higher levels of communication.

Okay, and so, just to ask again on fourth quarter sales so far, the growth in the fourth quarter is in line with what you're expecting for the quarter as a whole?

Yes.

Okay, thanks.

Once again, if you do have a question, please press star, then the number 1 on your telephone keypad.

Gentlemen, I'm showing no further questions at this time.

Do you have any closing remarks?

Yes.

Thank you, everybody, for joining the call.

We look forward in speaking to you shortly at the end of the year.

Thanks.

Thank you for participating in today's Option Care third quarter earnings conference call.

You may now disconnect.